Agent and methods for treating pain
AssigneeAllergan, Inc.
InventorsDaniel W. Gil, Kei R. Aoki
Life of this patent
Estimating the term…
Abstract
Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent are disclosed. The agent may include a clostridial neurotoxin, a fragment or a derivative thereof, attached to a targeting component, wherein the targeting component is selected from a group consisting of compounds which selectively binds at the alpha-2B or alpha-2B/alpha-2C adrenergic receptor subtype(s) as compared to other binding sites, for example, the alpha-2A adrenergic receptor subtype.
Claims46
An agent comprising:
- a therapeutic component, and
- a targeting ligand coupled to the therapeutic component, the targeting ligand being effective to bind to the alpha-2B or alpha-2B/alpha-2C adrenergic receptor subtype(s).
A method for making an agent for treating pain comprising the step of producing a polypeptide from a gene having codes for at least one component of the agent, wherein the agent comprises
- a therapeutic component, and
- a targeting ligand coupled to the therapeutic component, the targeting ligand being effective to bind to the alpha-2B or alpha-2B/alpha-2C adrenergic receptor subtype(s).
An agent comprising:
- a therapeutic component, and
- a targeting component coupled to the therapeutic component, the targeting component being represented by the formula:
An agent comprising:
- a therapeutic component, and
- a targeting component coupled to the therapeutic component, the targeting component comprising an antibody raised from an antigen component comprising a second extracellular loop, the second extracellular loop comprising an amino acid sequence of KGDQGPQPRGRPQCKLNQE (SEQ ID NO:
- 1).
Dependencies are inferred from the claim text.